NAS:AFMD (Germany)
Â
Business Description
Affimed NV
NAICS : 325414
SIC : 2836
Compare
Compare
Traded in other countries / regions
A28.Germany
•
0HL9.UK
•
AFMD.USA
Description
Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. The company is also developing single and combination therapies to treat cancers and other life-threatening diseases. Geographically, it derives a majority of revenue from the United States and also has a presence in Europe and Germany.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 11.9 | |||||
| Equity-to-Asset | 0.77 | |||||
| Debt-to-Equity | 0.1 | |||||
| Debt-to-EBITDA | -0.24 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | 1.16 | |||||
| Beneish M-Score | -3.09 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -5 | |||||
| 3-Year EBITDA Growth Rate | -15.2 | |||||
| 3-Year EPS without NRI Growth Rate | -14.2 | |||||
| 3-Year Book Growth Rate | 19.4 | |||||
| Future 3-5Y Total Revenue Growth Rate | 1.82 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 54.53 | |||||
| 9-Day RSI | 52.72 | |||||
| 14-Day RSI | 52.46 | |||||
| 6-1 Month Momentum % | -37.1 | |||||
| 12-1 Month Momentum % | -67.87 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.65 | |||||
| Quick Ratio | 5.63 | |||||
| Cash Ratio | 5.46 | |||||
| Days Sales Outstanding | 38.03 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -25.5 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -209.87 | |||||
| Net Margin % | -189.23 | |||||
| ROE % | -49.35 | |||||
| ROA % | -32.87 | |||||
| ROIC % | -152.14 | |||||
| ROC (Joel Greenblatt) % | -1637.12 | |||||
| ROCE % | -43.27 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 6.7 | |||||
| PB Ratio | 1.77 | |||||
| Price-to-Tangible-Book | 1.78 | |||||
| EV-to-EBIT | -1.21 | |||||
| EV-to-EBITDA | -1.24 | |||||
| EV-to-Revenue | 2.26 | |||||
| EV-to-FCF | -0.87 | |||||
| Price-to-Net-Current-Asset-Value | 1.83 | |||||
| Price-to-Net-Cash | 1.91 | |||||
| Earnings Yield (Greenblatt) % | -82.64 |
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:AFMD
Peter Lynch Chart
Performance
Dividend
Log
Annualized Return %
Total Annual Return %
Executives
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 42.957 | ||
| EPS (TTM) ($) | -0.615 | ||
| Beta | 2.21 | ||
| Volatility % | 47.78 | ||
| 14-Day RSI | 52.46 | ||
| 14-Day ATR ($) | 0.169205 | ||
| 20-Day SMA ($) | 2.155 | ||
| 12-1 Month Momentum % | -67.87 | ||
| 52-Week Range ($) | 1.4 - 6.91 | ||
| Shares Outstanding (Mil) | 149.34 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Affimed NV Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||
Affimed NV Analysis
Share your researchHeadlines
See More
No news.